Skip to main content
    B

    BioNexus Gene Lab Corp Common stock (BGLC)

    Official site

    BASIC MATERIALS • SPECIALTY CHEMICALS • NASDAQ

    $0.77
    -0.06 (-6.82%)

    Market Cap: $2.41M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    BioNexus Gene Lab Corp Common stock (BGLC) Financials: Revenue, Profit and Cash Flow

    Updated Aug 14, 2026. Financial statements from company filings, amounts in US dollars.

    BioNexus Gene Lab Corp Common stock reported revenue of $7.42M for the fiscal year ended Dec 31, 2025, down 21.9% from the year before. That year, net income was -$2.98M with a net margin of -40.2%, operating cash flow was -$1.84M and free cash flow was -$1.88M. The quarter ended Jun 30, 2026 had revenue of $76.16K and net income of -$286.45K.

    Revenue and Margins

    The operating margin was -39.9% in the fiscal year ended Dec 2025, the lowest of the 7 years shown with an operating margin. Over the 8 years to Dec 2025, revenue grew from $107.68K, a compound annual rate of 69.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$7.42M-21.9%14.6%-39.9%-40.2%
    Dec 2024$9.51M-2.7%13.6%-16.5%-16.8%
    Dec 2023$9.77M-10.6%13.6%-26.5%-26.9%
    Dec 2022$10.93M-18.2%11.5%-2.7%-3.3%
    Dec 2021$13.36M+17.3%17.0%7.9%5.6%
    Dec 2020$11.39M+8872.0%15.1%11.2%9.6%
    Dec 2019$126.95K-40.2%44.0%-217.2%-194.1%
    Dec 2018$212.33K+97.2%13.5%28.2%12.5%
    Dec 2017$107.68KN/A73.2%-118.8%-114.9%
    Dec 2016N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$7.42M$9.51M$9.77M$10.93M$13.36M$11.39M$126.95K$212.33K$107.68KN/A
    Cost of revenue$6.19M$6.53M$8.44M$9.67M$11.10M$9.68M$71.07K-$183.56K$28.87KN/A
    Gross profit$1.09M$1.29M$1.33M$1.26M$2.27M$1.72M$55.89K$28.77K$78.81KN/A
    Research and development$50.67K$47.51K$54.98K$0$0$0$0$0$0$0
    Operating income-$2.97M-$1.57M-$2.59M-$291.18K$1.06M$1.27M-$275.70K$59.90K-$127.91K-$840
    Net income-$2.98M-$1.60M-$2.63M-$355.97K$751.57K$1.09M-$246.47K$26.45K-$123.75K-$835
    EBITDA-$2.64M-$1.32M-$2.08M-$198.24K$1.15M$1.53M-$222.37K$67.06K-$104.38KN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$76.16K$22.84K$483.76K$2.54M$2.26M$2.14M$2.52M$2.63M$1.97M$2.38M$2.27M$2.55M
    Gross profit$12.98K-$790-$3.98K$377.69K$368.02K$343.49K$309.23K$326.54K$288.72K$365.03K$266.56K$354.33K
    Operating income-$282.40K-$540.49K-$1.03M-$702.51K-$611.29K-$618.42K-$416.22K-$1.34M$259.17K-$79.03K$257.75K-$2.53M
    Net income-$286.45K-$543.58K-$1.12M-$708.99K-$616.17K-$623.33K-$629.39K-$1.35M$199.10K$177.32K$308.46K-$2.61M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $59.15K by $2.32M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$9.25M$10.43M$11.40M$8.74M$9.57M$10.12M$1.23M$1.65M$1.27M$26
    Current assets$5.45M$7.43M$8.05M$6.02M$7.15M$7.99M$882.57K$1.30M$999.72K$26
    Cash and equivalents$2.38M$1.58M$2.62M$611.85K$578.51K$699.59K$366.04K$659.24K$839.14K$26
    Total liabilities$637.86K$2.11M$1.74M$2.08M$2.39M$3.45M$108.87K$130.31K$1.18M$1.34K
    Short-term debt$59.15K$50.82K$47.83K$16.57K$39.51K$45.75K$32.14K$19.13KN/AN/A
    Shareholder equity$8.61M$8.32M$9.66M$6.67M$7.18M$6.66M$1.12M$1.52M$94.63K-$1.31K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$8.73M$9.04M$9.25M$7.62M$9.42M$9.48M$10.43M$11.00M$11.14M$11.16M$11.40M$11.47M
    Total liabilities$947.98K$946.88K$637.86K$804.97K$1.90M$1.71M$2.11M$1.61M$1.59M$1.82M$1.74M$1.78M
    Cash and equivalents$1.23M$1.34M$4.04M$1.15M$814.18K$1.09M$4.38M$2.06M$2.20M$2.49M$5.93M$4.70M
    Shareholder equity$7.78M$8.09M$8.61M$6.82M$7.52M$7.77M$8.32M$9.39M$9.55M$9.34M$9.66M$9.69M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$1.84M-$2.09M-$1.82M$551.82K$9.16K$552.68K-$217.27K-$274.08K$357.22K-$835
    Capital expenditures$36.97K$226.99K$149.40K$54.17K$3.16K$421.62K$12.82K$39.62K$314.82K$0
    Free cash flow-$1.88M-$2.32M-$1.97M$497.65K$6.00K$131.06K-$230.09K-$313.70K$42.40K-$835
    Dividends paid$22.11K$68.13K$115.38K$7.79K$22.04K$6.31KN/AN/AN/AN/A
    Investing cash flow$944.75K$418.20K-$1.79M-$450.50K-$490.57K$1.32M-$12.82K-$51.70K-$5.31M-$5.31M
    Financing cash flow$298.84K$3.98K$6.27M$108.17K-$28.22K-$4.95K-$180.81K$742.94K$5.78M$638
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$422.49K-$147.67K$961.06K-$1.24M-$737.91K-$824.07K$219.20K-$1.60M-$672.27K-$37.15K-$782.53K-$899.35K
    Capital expenditures$250$325$977$5.48K$21.46K$9.05K$4.02K$199.19K$1.83K$21.95K$937$134.00K
    Free cash flow-$422.74K-$148.00K$960.09K-$1.24M-$759.37K-$833.12K$215.18K-$1.80M-$674.11K-$59.10K-$783.46K-$1.03M
    Last 12 quarters

    Frequently Asked Questions About BGLC

    What is BioNexus Gene Lab Corp Common stock's annual revenue?

    BioNexus Gene Lab Corp Common stock reported revenue of $7.42M for the fiscal year ended Dec 31, 2025.

    How fast is BioNexus Gene Lab Corp Common stock's revenue growing?

    Revenue was down 21.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -12.1%.

    Is BioNexus Gene Lab Corp Common stock profitable?

    No. BioNexus Gene Lab Corp Common stock reported net income of -$2.98M for the fiscal year ended Dec 31, 2025, with a net margin of -40.2%.

    How much free cash flow does BGLC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$1.84M minus capital expenditures of $36.97K produced free cash flow of -$1.88M.

    How much debt does BioNexus Gene Lab Corp Common stock have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $59.15K and cash and equivalents of $2.38M.